Bucindolol hydrochloride is under clinical development by ARCA biopharma and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Bucindolol hydrochloride’s likelihood of approval (LoA) and phase transition for Atrial Fibrillation took place on 16 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Bucindolol hydrochloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Bucindolol hydrochloride overview

Bucindolol hydrochloride (Gencaro) is under development for the treatment of atrial fibrillation and atrial flutter. It is formulated as a capsule and administered orally. The drug candidate is a mild vasodilator and also acts by targeting beta adrenergic receptors. The drug candidate was also under development for the treatment of chronic heart failure.

ARCA biopharma overview

ARCA biopharma (ARCA), formerly Nuvelo is a company that develops genetically targeted therapies for cardiovascular diseases. The company’s product candidate include Gencaro, a mild vasodilator and investigational pharmacologically unique beta-blocker that is being developed for the treatment and prevention of atrial fibrillation in patients with heart failure and reduced left ventricular ejection fraction. ARCA also develops AB171, a thiol-substituted isosorbide mononitrate for genetically targeted treatment of peripheral arterial disease and heart failure; and rNAPc2, a potential treatment for patients hospitalized with COVID-19. It provides medical treatment to the individual genetic characteristics of each patient and personalized medicine approach to drug development. The company works in partnership with universities to improve the health of cardiovascular patients. ARCA is headquartered in Westminster, Colorado, the US.

Quick View Bucindolol hydrochloride LOA Data

Report Segments
  • Innovator
Drug Name
  • Bucindolol hydrochloride
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.